-
-
-
-
-
-
-
Takeda psoriasis drug shows skin clearance in Phase 3 trials
-
-
-
-
-
-
-
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
-
-
-
-
-
-
-
Takeda (TAK) Takeda's zasocitinib shows clear skin results in psoriasis trials
-
-
-
-
-
-
-
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
-
-
-
-
-
-
-
Takeda reports positive phase 3 results for zasocitinib psoriasis drug
-
-
-
-
-
-
-
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
-
-
-
-
-
-
-
Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
-
1,186,524 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

